Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extended Dosing, Two-Phase Study of MDX-010 [ipilimumab] as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG [melanoma vaccine] in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma

Next Previous
Trial Profile

An Extended Dosing, Two-Phase Study of MDX-010 [ipilimumab] as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG [melanoma vaccine] in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Melanoma vaccine
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 20 Apr 2010 'Bristol-Myers Squibb' added as trial affiliate and sponsor as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Actual patient number (75) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top